Table 6 Characterization of NR4A agonist 36 and negative control 29 demonstrating high chemical tool quality44,45
From: Development of Nurr1 agonists from amodiaquine by scaffold hopping and fragment growing
|
| |
|---|---|---|
36 | 29 | |
EC50(Nurr1) | 0.090 ± 0.005 µM | no activation (10 µM) |
EC50(Nur77) | 0.33 ± 0.04 µM | no activation (10 µM) |
EC50(NOR-1) | 0.11 ± 0.03 µM | no activation (10 µM) |
EC50(NBRE) | no activation (1 µM) | no activation (10 µM) |
EC50(NurRE) | 0.094 ± 0.003 µM | no activation (10 µM) |
EC50(DR5) [+0.1 µM BEX] | 0.165 ± 0.004 µM [0.032 ± 0.007 µM] | no activation (10 µM) |
Kd(Nurr1 LBD) | 0.17 µM | no bindingb |
NR selectivityc | inactive (3 µM) | n.d. |
toxicityd | inactive (10 µM) | inactive (10 µM) |
aq. solubility | 6.8 mg/L | 4.1 mg/L |
SlogPe | 4.87 | 4.54 |
